- December 14, 2006
- Cerexa to be acquired by Forest Laboratories for $480 million plus potential $100 million milestone payment
- November 1, 2006
- TargeGen initiates Phase I clinical trial of topical AMD drug TG100801
- November 1, 2006
- Cerexa expands portfolio of novel anti-infective therapies through in-licensing agreement with Meiji Seika Kaisha
- October 23, 2006
- BrainCells and Organon to collaborate in discovery and development of CNS drugs
- October 4, 2006
- Roche and Plexxikon enter major cancer partnership
- October 3, 2006
- Plexxikon files IND application for targeted cancer therapeutic PLX4032
- September 13, 2006
- Anthera Pharmaceuticals secures $36m venture financing to initiate clinical programs
- September 13, 2006
- Dynogen initiates phase 1b trial of DDP733 in gastroesophageal reflux disease (GERD)
- September 6, 2006
- Anthera licenses anti-inflammatory products from Eli Lilly and Shionogi
- August 15, 2006
- LipoScience, Inc. Closes $13 Million in Series F Financing
- August 10, 2006
- BrainCells, Inc. In-Licenses Clinical-Stage CNS Compound From Mitsubishi Pharma
- August 8, 2006
- FlowCardia, Inc. Completes Enrollment in the FACTOR Coronary Pivotal Study and Initiates the PATRIOT Peripheral Pivotal Study With the CROSSER(TM) CTO Recanalization System
- August 2, 2006
- Cerexa Reports Positive Top-Line Results for Phase 2 Clinical Trial of Ceftaroline
- June 29, 2006
- FDA Grants Fast Track Designation For TargeGen TG100-115 Cardiovascular Compound
- May 31, 2006
- Panacos Announces Study Elucidating PA-457's Mechanism of Action Published in Journal of Virology;Findings Corroborate Novel Target and Support Further Maturation Inhibitor Development
- May 4, 2006
- Methylgene Completes Private Placement of $19.9 Million
- April 10, 2006
- Bayhill Therapeutics Raises an Additional $15.8 Million
- April 5, 2006
- Cerexa Announces Completion of Enrollment in Ceftaroline Phase 2 Trial
- March 14, 2006
- Dynogen Initiates Phase II Trial of DDP225
- March 14, 2006
- FDA Grants Cerexa Fast Track Designation for PPI-0903
- January 17, 2006
- CoLucid Pharmaceuticals Announces $16.5 Million Series A Financing